Platelet Immune Responses in Aging and Influenza
衰老和流感中的血小板免疫反应
基本信息
- 批准号:9282389
- 负责人:
- 金额:$ 36.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-01 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AgingAgonistAntibody ResponseBlood PlateletsCellsCellular MembraneClinicalCytoplasmic GranulesDataDevelopmentDiseaseEffector CellElderlyFamilyFamily memberFunctional disorderGenesGenetic TranscriptionGrantHumanIFITM1 geneImmuneImmune responseImpairmentInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza vaccinationIntegral Membrane ProteinInterferonsInvestigationMaintenanceMediatingMegakaryocytesMembraneModelingMorbidity - disease rateOutcomePathogenesisPathway interactionsPatientsPatternPost-Transcriptional RegulationPredispositionPreventionProtein FamilyProteinsProteomeRecordsResearchResearch PersonnelRiskRoleScientistSeverity of illnessTechniquesViral Respiratory Tract InfectionVirus Replicationadverse outcomeage relatedbasebench to bedsideclinically relevantdifferential expressionhigh riskhuman subjectimmune functionimmunoregulationimmunosenescenceimprovedinfluenzavirusmortalitymultidisciplinaryolder patientpreventprospectiveprotein expressionpublic health relevanceresponsetooltranscriptometranscriptome sequencing
项目摘要
DESCRIPTION (provided by applicant): Platelets are emerging as dynamic and versatile immune effector cells that mediate host responses to respiratory viral infections, including influenza. In the elderly, influenza infections are common and cause substantial morbidity and mortality. Our grant, entitled "Platelet Immune Responses in Aging and Influenza" will examine age-related changes in newly-discovered platelet immune proteins and how impaired responses contribute to adverse clinical outcomes. This family of proteins, the interferon-induced transmembrane proteins (IFITMs), prevents influenza viral replication and infectivity. IFITM family members have not previously been described in human platelets. Our specific aims and hypotheses are based on a rich pool of preliminary data demonstrating that platelets from older adults have diminished expression of IFITMs during influenza infection and following influenza vaccination. We also found that the inability to upregulate IFITM protein expression correlates with an increased risk of influenza-related mortality. In our preliminary studies, there is evidenc that expression of IFITM occurs at transcriptional and post-transcriptional checkpoints in platelet
precursors (e.g., megakaryocytes) and mature platelets. In this application, we will determine, in settings of influenza infection and following influenza vaccination, whether aging alters the induction of IFITM proteins in human platelets. We will also establish whether age-related impairments in IFITM induction contribute to influenza-related illness severity and mortality. Moreover, we will dissect the mechanisms and patterns of IFITM expression in human platelets and model megakaryocytes derived from young and older human subjects. While we will investigate IFITM family members in detail, we will also use deep RNA-sequencing (RNA-seq) to identify other candidate immunomodulatory genes in platelets and megakaryocytes that are altered in older adults. Candidates identified by RNA-seq will be examined in-depth at the message, protein, and/or activity level. These investigations are the first studies to characterize
IFITMs in megakaryocytes and platelets. As our investigations will be accomplished using human subjects and primary human cells, our findings will have immediate clinical relevance. Our multi-disciplinary team unites young and senior investigators, clinicians, and basic scientists. All techniques and tools are established and in place and we have proven track records of paradigm-shifting, bench-to-bedside discovery research. Thus, we are poised to determine how aging alters immune sensing by platelets and megakaryocytes and define new mechanisms regulating influenza-induced platelet immune responses in the elderly.
描述(由申请方提供):血小板是一种动态和多功能的免疫效应细胞,介导宿主对呼吸道病毒感染(包括流感)的应答。在老年人中,流感感染是常见的,并导致大量的发病率和死亡率。我们的赠款,题为“血小板免疫反应在衰老和流感”将检查年龄相关的变化,新发现的血小板免疫蛋白和受损的反应如何导致不良的临床结果。干扰素诱导的跨膜蛋白(IFITMs)是一种蛋白质家族,可防止流感病毒复制和感染。IFITM家族成员以前未在人血小板中描述过。我们的具体目标和假设是基于丰富的初步数据库,表明老年人的血小板在流感感染期间和流感疫苗接种后IFITM的表达减少。我们还发现,IFITM蛋白表达不能上调与流感相关死亡率的风险增加相关。在我们的初步研究中,有证据表明IFITM的表达发生在血小板的转录和转录后检查点。
前体(例如,巨核细胞)和成熟血小板。在本申请中,我们将确定在流感感染的情况下和流感疫苗接种后,衰老是否会改变人血小板中IFITM蛋白的诱导。我们还将确定IFITM诱导中与年龄相关的损伤是否会导致流感相关疾病的严重程度和死亡率。此外,我们将剖析IFITM表达的机制和模式在人血小板和模型巨核细胞来自年轻和老年人受试者。虽然我们将详细研究IFITM家族成员,但我们还将使用深度RNA测序(RNA-seq)来鉴定老年人血小板和巨核细胞中发生改变的其他候选免疫调节基因。通过RNA-seq鉴定的候选人将在信息、蛋白质和/或活性水平上进行深入研究。这些调查是第一次研究,
巨核细胞和血小板中的IFITM。由于我们的研究将使用人类受试者和原代人类细胞完成,我们的发现将具有直接的临床意义。我们的多学科团队将年轻和高级研究人员,临床医生和基础科学家团结在一起。所有的技术和工具都已经建立并到位,我们已经证明了范式转变,从实验室到床边的发现研究的记录。因此,我们准备确定衰老如何改变血小板和巨核细胞的免疫感应,并确定调节老年人流感诱导的血小板免疫反应的新机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Thomas Rondina其他文献
Matthew Thomas Rondina的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Thomas Rondina', 18)}}的其他基金
Translational Control of Megakaryocyte and Platelet Function in Sepsis
脓毒症中巨核细胞和血小板功能的转化控制
- 批准号:
9577464 - 财政年份:2018
- 资助金额:
$ 36.03万 - 项目类别:
Platelet Translational Control Mechanisms in Stroke and Vascular Cognitive Dementia
中风和血管性认知痴呆中的血小板翻译控制机制
- 批准号:
10281770 - 财政年份:2018
- 资助金额:
$ 36.03万 - 项目类别:
Translational Control of Megakaryocyte and Platelet Function in Sepsis
脓毒症中巨核细胞和血小板功能的转化控制
- 批准号:
10210293 - 财政年份:2018
- 资助金额:
$ 36.03万 - 项目类别:
Platelet Immune Responses in Aging and Influenza
衰老和流感中的血小板免疫反应
- 批准号:
8625156 - 财政年份:2014
- 资助金额:
$ 36.03万 - 项目类别:
Platelet Immune Responses in Aging and Influenza
衰老和流感中的血小板免疫反应
- 批准号:
8852034 - 财政年份:2014
- 资助金额:
$ 36.03万 - 项目类别:
The Regulation of Inflammatory Gene Responses in Aging
衰老过程中炎症基因反应的调节
- 批准号:
8183844 - 财政年份:2011
- 资助金额:
$ 36.03万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 36.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




